Sprint Bioscience AB (OSTO:SPRINT) Total Operating Expense: kr55.6 Mil (TTM As of Mar. 2026)


OSTO:SPRINT Sprint Bioscience AB OSTO:SPRINT
32 GF Score
Price kr3.70
GF Value kr2.18
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sprint Bioscience AB Total Operating Expense?

Sprint Bioscience AB OSTO:SPRINT -9.09% 32 Total Operating Expense is kr55.6 Mil as of Mar. 2026. GuruFocus rates OSTO:SPRINT with a GF Score™ of 32/100 and a GF Value™ of kr2.18 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Sprint Bioscience AB's Total Operating Expense for the three months ended in Mar. 2026 was kr12.9 Mil. Sprint Bioscience AB's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr55.6 Mil.

Sprint Bioscience AB Total Operating Expense Related Terms

Sprint Bioscience AB Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Sprint Bioscience AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sprint Bioscience AB Total Operating Expense Chart

Sprint Bioscience AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.14 0.00 44.31 56.71 56.54

Sprint Bioscience AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.08 15.58 11.83 15.34 12.87
OSTO:SPRINT
32GF Score
Sprint Bioscience AB OSTO:SPRINT
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sprint Bioscience AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr55.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of kr55.6 Mil mean?
Sprint Bioscience AB (OSTO:SPRINT) has a Total Operating Expense of kr55.6 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Sprint Bioscience AB and its competitors.
Is Sprint Bioscience AB's Total Operating Expense too high?
Sprint Bioscience AB's current Total Operating Expense is kr55.6 Mil. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Total Operating Expense compare to VRTX and REGN?
Sprint Bioscience AB's Total Operating Expense of kr55.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Sprint Bioscience AB and its competitors. Sprint Bioscience AB's current Total Operating Expense is kr55.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr3.70 — trading 69.7% above its estimated fair value. The current Total Operating Expense is kr55.6 Mil. Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current Total Operating Expense is kr55.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?

Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued. The current stock price of kr3.70 is trading 69.7% above its estimated GF Value™ of kr2.18. GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPRINT:

  • Total Operating Expense: kr55.6 Mil
  • GF Value™: kr2.18 vs. price of kr3.70 (69.7% above fair value)
  • GF Score™: 32/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sprint Bioscience AB Business Description

Other Exchanges 5JA1:Germany
Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score

Get the complete analysis for OSTO:SPRINT

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.70
Price
kr2.18
GF Value